JP2020517262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517262A5 JP2020517262A5 JP2019556941A JP2019556941A JP2020517262A5 JP 2020517262 A5 JP2020517262 A5 JP 2020517262A5 JP 2019556941 A JP2019556941 A JP 2019556941A JP 2019556941 A JP2019556941 A JP 2019556941A JP 2020517262 A5 JP2020517262 A5 JP 2020517262A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- antibody
- less
- extracellular domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 238000000034 method Methods 0.000 claims 11
- 102000004388 Interleukin-4 Human genes 0.000 claims 10
- 108090000978 Interleukin-4 Proteins 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 10
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 claims 9
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 claims 9
- 102000003816 Interleukin-13 Human genes 0.000 claims 9
- 108090000176 Interleukin-13 Proteins 0.000 claims 9
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 7
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 7
- 241000283073 Equus caballus Species 0.000 claims 5
- 241000282326 Felis catus Species 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000007781 signaling event Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023028068A JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488509P | 2017-04-21 | 2017-04-21 | |
| US62/488,509 | 2017-04-21 | ||
| PCT/US2018/028507 WO2018195388A1 (en) | 2017-04-21 | 2018-04-20 | Il4/il13 receptor molecule for veterinary use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028068A Division JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517262A JP2020517262A (ja) | 2020-06-18 |
| JP2020517262A5 true JP2020517262A5 (cg-RX-API-DMAC7.html) | 2021-05-27 |
| JP7657548B2 JP7657548B2 (ja) | 2025-04-07 |
Family
ID=63856393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556941A Active JP7657548B2 (ja) | 2017-04-21 | 2018-04-20 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| JP2023028068A Active JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028068A Active JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11970526B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612555A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7657548B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250057131A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110770250B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018254542B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019021812A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059731A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012570A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018195388A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| KR20250057131A (ko) | 2017-04-21 | 2025-04-28 | 엘랑코 유에스 인코포레이티드 | 수의학 용도를 위한 il4/il13 수용체 분자 |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| AU2021259785A1 (en) * | 2020-04-22 | 2022-11-17 | Elanco Us Inc. | IL4/IL13 receptor molecules for veterinary use |
| CN116323659A (zh) * | 2020-06-12 | 2023-06-23 | 北京伟德杰生物科技有限公司 | 融合多肽 |
| EP4388006A1 (en) | 2021-08-20 | 2024-06-26 | Intervet International B.V. | Homodimer fusion proteins for treating atopic dermatitis |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
| US7083949B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| NZ512942A (en) | 1998-12-14 | 2004-01-30 | Univ Johns Hopkins | Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| EP1268794A2 (en) | 2000-04-07 | 2003-01-02 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| EP2292665B1 (en) | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US7208579B2 (en) | 2003-05-30 | 2007-04-24 | The Regents Of The University Of California | IL4 receptor antagonists for horse, dog and cat |
| DK2805728T3 (da) | 2003-12-23 | 2020-04-20 | Genentech Inc | Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf |
| CN1922204A (zh) | 2004-02-27 | 2007-02-28 | 瑞泽恩制药公司 | Il－4/il－13特异性的多肽和其治疗应用 |
| JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用 |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| EP2674440B1 (en) * | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| WO2008073463A2 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| WO2009061911A1 (en) * | 2007-11-06 | 2009-05-14 | Wyeth | Assays and methods for evaluating multimeric complexes |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| JP2014519808A (ja) | 2011-04-29 | 2014-08-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ４／ｉｌ１３に結合する反復タンパク質及び使用 |
| WO2013087660A1 (en) | 2011-12-13 | 2013-06-20 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| CN104755495A (zh) * | 2012-08-21 | 2015-07-01 | 赛诺菲 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| AU2016239858B2 (en) | 2015-04-02 | 2021-07-01 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| HK1255329A1 (zh) * | 2015-07-29 | 2019-08-16 | 纳米提克斯有限责任公司 | 用於清除可溶性生物分子的模块化组合物及其相关方法 |
| AU2017336546C1 (en) | 2016-09-27 | 2025-05-29 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| KR20250057131A (ko) | 2017-04-21 | 2025-04-28 | 엘랑코 유에스 인코포레이티드 | 수의학 용도를 위한 il4/il13 수용체 분자 |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| AU2021259785A1 (en) | 2020-04-22 | 2022-11-17 | Elanco Us Inc. | IL4/IL13 receptor molecules for veterinary use |
-
2018
- 2018-04-20 KR KR1020257012785A patent/KR20250057131A/ko active Pending
- 2018-04-20 JP JP2019556941A patent/JP7657548B2/ja active Active
- 2018-04-20 KR KR1020197032241A patent/KR20200006528A/ko not_active Ceased
- 2018-04-20 WO PCT/US2018/028507 patent/WO2018195388A1/en not_active Ceased
- 2018-04-20 EP EP18788175.0A patent/EP3612555A4/en active Pending
- 2018-04-20 CN CN201880041160.7A patent/CN110770250B/zh active Active
- 2018-04-20 BR BR112019021812-2A patent/BR112019021812A2/pt unknown
- 2018-04-20 MX MX2019012570A patent/MX2019012570A/es unknown
- 2018-04-20 AU AU2018254542A patent/AU2018254542B2/en active Active
- 2018-04-20 US US16/605,356 patent/US11970526B2/en active Active
- 2018-04-20 CA CA3059731A patent/CA3059731A1/en active Pending
-
2023
- 2023-02-27 JP JP2023028068A patent/JP7776461B2/ja active Active
- 2023-03-20 AU AU2023201726A patent/AU2023201726B2/en active Active
-
2024
- 2024-03-27 US US18/617,972 patent/US20240270820A1/en active Pending